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for AKI sCr were 280 ng/ml for plasma (PPV 80%; NPV 79%), 
and 250 ng/ml for urinary NGAL (PPV 58%; NPV 78%).  Con-
clusions: NGAL can be used to distinguish oliguria due to the 
functional adaptation from AKI sCr , directing resources to pa-
tients more likely to develop AKI sCr .  
 © 2016 The Author(s)
Published by S. Karger AG, Basel 
 Introduction 
 Oliguria is defined as a drop in urine output to less than 
0.5 ml/kg/h and frequently occurs in critically ill patients. 
Oliguria – in the absence of a serum creatinine increase – 
in a patient without invasive monitoring of cardiac output 
and fluid status is a challenge for the intensivist’s decision 
to either continue fluid resuscitation in order to treat pre-
sumed hypovolemia and thereby prevent the onset of 
acute kidney injury (AKI)  [1] or limit fluid intake to avoid 
the adverse effects of fluid overload. Indeed, a decrease in 
urine output can be due to hypovolemia, transiently inad-
equate perfusion, or renal cell injury  [2] . Accordingly, ol-
iguria by itself is at best a moderate predictor for AKI de-
fined as a serum creatinine increase (AKI sCr )  [3, 4] .
 Traditionally, urinary markers such as the fractional 
excretion of sodium or urea are used to differentiate be-
tween prerenal or renal causes of AKI. However, its util-
ity in critically ill patients has been challenged due to con-
founders such as fluid resuscitation, diuretics and vasoac-
tive drugs, and by a poor correlation with severity of AKI 
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 Abstract 
 Background: Oliguria occurs frequently in critically ill pa-
tients, challenging clinicians to distinguish functional adap-
tation from serum-creatinine-defined acute kidney injury 
(AKI sCr ). We investigated neutrophil gelatinase-associated li-
pocalin (NGAL)’s ability to differentiate between these 2 con-
ditions.  Methods: This is a post-hoc analysis of a prospective 
cohort of adult critically ill patients. Patients without oliguria 
within the first 6 h of admission were excluded. Plasma and 
urinary NGAL were measured at 4 h after admission. AKI sCr 
was defined using the AKI network criteria with pre-admis-
sion serum creatinine or lowest serum creatinine value dur-
ing the admission as the baseline value. Hazard ratios for 
AKI sCr occurrence within 72 h were calculated using Cox re-
gression and adjusted for risk factors such as sepsis, pre-ad-
mission serum creatinine, and urinary output. Positive pre-
dictive values (PPV) and negative predictive values (NPV) 
were calculated for the optimal cutoffs for NGAL.  Results: 
Oliguria occurred in 176 patients, and 61 (35%) patients de-
veloped AKI sCr . NGAL was a predictor for AKI sCr in univariate 
and multivariate analysis. When NGAL was added to a multi-
variate model including sepsis, pre-admission serum creati-
nine and lowest hourly urine output, it outperformed the lat-
ter model (plasma p = 0.001; urinary p = 0.048). Cutoff values 
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 [5] . Recently, the advent of renal biomarkers has seen 
many studies investigating their use as early predictors 
for AKI  [6] . Neutrophil gelatinase-associated lipocalin 
(NGAL), one of those biomarkers, is produced in the dis-
tal nephron and its concentration increases when tubu-
lar cellular injury is present  [7–9] . The increase in NGAL 
levels in case of cellular damage, that is, acute tubular in-
jury – precedes a rise in serum creatinine  [9–11] .
 To address whether NGAL is able to identify those crit-
ically ill patients with early oliguria that will develop 
 AKI sCr, we performed a post-hoc analysis in a previously 
described cohort  [12] . Our hypothesis was that low NGAL 
concentrations in oliguric critically patients are most like-
ly due to hemodynamic or hormonal compensation mech-
anisms, whereas a high NGAL concentration heralds 
AKI sCr . Our objective was to investigate whether NGAL, 
measured after the occurrence of oliguria, can identify 
AKI sCr within the first 72 h in patients with oliguria occur-
ring within 6 h of intensive care unit (ICU) admission.
 Patients and Methods 
 Patient Selection 
 We performed a post-hoc analysis on a prospectively gathered 
biomarker dataset from a previously published cohort  [12, 13] . 
The institutional review board of Erasmus MC, University Medical 
Center Rotterdam, The Netherlands, approved the initial study. 
All consecutive admitted patients between September 2007 and 
April 2008 were eligible for enrollment. The original exclusion cri-
teria were age under 18 years, refusal of consent, nephrectomy, 
chronic kidney disease (glomerular filtration rate using pre-ad-
mission serum creatinine <60 ml/min/1.73 m 2 ), end-stage renal 
disease, and renal transplantation. Deferred consent was used, and 
written informed consent was obtained from all participants or 
their health care proxy  [14] . From this dataset, we excluded read-
missions and all patients who did not develop oliguria within the 
first 6 h of the ICU admission ( fig. 1 ). All patients without a re-
corded weight or without sufficient urine output data within 6 h of 
ICU admission, that is, only one recorded measurement during the 
6-hour period were excluded.
 Data Collection and Definitions 
 Data were retrospectively collected from our electronic patient 
data monitoring system (Picis Clinical Solutions, Wakefield, 
Mass., USA). Urine output was prospectively recorded by the at-
tending nurses in irregular intervals, depending on the urine out-
put, ranging from 1 h up to 3 h. We assumed a constant rate of 
urine flow within each interval, and calculated the hourly urine 
output by averaging the volume over each hour in that interval. 
Oliguria was defined as urine output less than 0.5 ml/kg/h. The 
mean urine output and lowest hourly urine output were calculated 
from the urine output available in the first 6 h. Furosemide and 
bumetanide were pooled together when looking at diuretics use. 
Serum creatinine was measured at admission and at least once dai-
ly at 6: 00 a.m. Pre-admission serum creatinine was defined as the 
steady state level 4 weeks before admission  [12] . Patients who re-
quired renal replacement therapy were identified, which in our 
clinical setting is initiated for metabolic disorders due to AKI or 
diuretic-resistant fluid overload.
 We collected the following variables from the clinical chart: 
gender; age; Acute Physiology and Chronic Health Evaluation and 
the Sequential Organ Failure Assessment score at day of admission; 
the presence of the systemic inflammatory response syndrome cri-
teria was scored during the first 6 h of ICU admission; the presence 
of sepsis at admission defined according to American College of 
Chest Physicians/Society of Critical Care Medicine consensus cri-
teria  [1] and the presumed or confirmed source. The primary ad-
mission diagnosis was collected for each patient and categorized to 
either respiratory failure, gastrointestinal hemorrhage, liver failure, 
esophagectomy, vascular surgery, gastrointestinal surgery, liver 
transplant, multi-trauma, subarachnoid hemorrhage, neuro-trau-
ma and neurosurgery. Admission diagnoses were then pooled ac-
cording to medical, surgical or neurological etiologies.
 Plasma and urinary NGAL samples were collected and mea-
sured in the original study at admission and at 7 time points there-
after (4, 8, 24, 36, 48, 60 and 72 h) using the Triage ® point-of-care 
immunoassay (Biosite Inc., San Diego, Calif., USA), which mea-
sures the NGAL monomer  [12] . AKI sCr was defined according to 
the AKI network (AKIN) serum creatinine criteria using the pre-
admission serum creatinine as the baseline value  [15] . If pre-admis-
sion serum creatinine was not available, the lowest value during 
Original dataset
n = 632
Included into analysis
n = 176
AKIsCrn = 61
No AKIsCrn = 115
Readmission
n = 36
Insufficient urinary data
n = 155
No oliguria within 6 h
n = 263
Urinary data available
n = 439
AKIsCrn = 109
No AKIsCrn = 330
 Fig. 1. Inclusion flow chart. This figure shows the number of pa-
tients included in the original article  [12] , and the exclusion crite-
ria and number of patients excluded from this post-hoc analysis. 
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the admission was used as a surrogate  [16] . Patients who did not 
develop AKI sCr in the first 72 h of ICU admission were allocated to 
the noAKI sCr group, and those who did were allocated to the  AKI sCr 
group. If in AKI sCr the lowest serum creatinine value during the 
admission was measured after the highest serum creatinine value 
within the first 72 h, it was categorized as transient AKI sCr  [16] .
 Statistical Analysis 
 Since most data were not normally distributed (Kolmogorov–
Smirnov test, p < 0.05), data were reported as median with inter-
quartile range. Missing plasma and urinary NGAL data were im-
puted using multiple imputations with the MICE package, using 
predictive mean matching of NGAL at admission, 4 and 8 h after 
admission with 25 imputations across 50 iterations  [17] . Categor-
ical variables were summarized by numbers and percentages. Dif-
ferences between the 2 groups were compared using the Mann–
Whitney U test for continuous variables, and the Fisher’s exact test 
for categorical variables.
 NGAL measured 4 h after admission was used for all analyses 
because it was the closest measured value after most occurrences of 
oliguria. Cox’s proportional hazard regression analysis was used to 
estimate the effect of NGAL, pre-admission serum creatinine, sep-
sis, mean urine output, lowest hourly urine output and duration of 
oliguria as predictors for AKI sCr . These variables were also inputted 
in a multivariate model, one for plasma NGAL and one for urinary 
NGAL and variables were subsequently eliminated using a stepwise 
backward selection method. A multivariate model without NGAL 
was created using a stepwise backward selection method to inves-
tigate the additive value of NGAL to the multivariate model. The 
continuous net reclassification improvement (NRI) and the inte-
grated discrimination improvement (IDI) were calculated to quan-
tify the improvement in area under the receiver operating charac-
teristics curves (AUROC) after adding NGAL. The NRI statistic 
describes the proportion of patients based on the new model having 
assigned a probability for AKI sCr closer to 1 for those with AKI sCr 
and closer to 0 for patients without AKI sCr . The IDI statistic de-
scribes the mean change in probabilities (increases for events and 
decreases in non-events) between the new and old model.
 To assess whether NGAL – either univariate or in a multivariate 
model – leads to an improvement in AKI sCr prediction, we first com-
pared the AUROC for the NGAL models against the  AUROC of the 
multivariate model without NGAL at 24, 48 and 72 h after admis-
sion. Optimal cutoff values at 24, 48 and 72 h after admission were 
estimated for univariate plasma and urinary NGAL and admission 
serum creatinine using Youden’s J-statistic  [18] .
 All analyses were performed using R statistical software pack-
age (R Foundation for Statistical Computing, Vienna, Austria) 
 [19] and the time-dependent AUROCs for the Cox’s regression 
models were calculated and compared with the timeROC package 
 [20] . A p value <0.05 was defined as significant, and exact p values 
were given unless p < 0.001.
 Results 
 Of the 632 patients included in the original study and 
after excluding readmissions and records with insuffi-
cient urinary data from the original cohort  [12] , 439 pa-
tients remained with an AKI sCr incidence of 25% ( fig. 1 ). 
After excluding patients without oliguria within the first 
6 h of ICU admission, 176 patients remained. In 10 pa-
tients (5.7%), pre-admission serum creatinine was not 
available. The general characteristics are reported in  ta-
ble 1 . Sixty-one patients (35%) developed AKI sCr during 
the first 72 h of ICU admission. AKI sCr occurred relative-
ly early in the ICU admission (87% within 24 h), and 
Table 1.  General characteristics
AKIsCr NoAKIsCr p value
Number 61 115
Male 37 (61) 75 (65) 0.622
Age, years 62 (47–72) 61 (49–71) 0.889
APACHE II score 22 (17–28) 16 (13–20) <0.001
SOFA score on day of
 admission 8 (6–12) 4 (1.5–6) <0.001
Pre-admission serum
 creatinine, μmol/l 75 (60–90) 70 (60–80) 0.139
Admission serum  creatinine,
μmol/l 115 (84–148) 68 (56–82) <0.001
Lowest serum creatinine
during admission, μmol/l 73 (53–108) 56 (46–68) <0.001
Admission type
Medical 39 (64) 36 (31) <0.001
Surgical 19 (31) 61 (53) 0.007
Neurological 3 (5) 18 (16) 0.049
Admission diagnosis
Respiratory failure 14 (23) 10 (9) 0.011
Gastrointestinal
 hemorrhage 4 (7) 5 (4) 0.500
Liver failure 2 (3) 0 (0) 0.119
Esophagectomy 3 (5) 19 (17) 0.031
Vascular surgery 6 (10) 10 (9) 0.789
Gastrointestinal surgery 7 (11) 13 (11) 1.000
Liver transplant 2 (3) 1 (1) 0.276
Multitrauma 4 (7) 5 (4) 0.500
Subarachnoid
 hemorrhage 0 (0) 7 (6) 0.097
Neurotrauma 1 (2) 7 (6) 0.265
Neurosurgery (elective
and emergency) 3 (5) 17 (15) 0.078
SIRS ≥2 criteria 52 (85) 81 (70) 0.042
Sepsis 23 (38) 12 (10) <0.001
Pulmonary 10 (16) 6 (5) 0.025
Abdominal 11 (18) 6 (5) 0.013
Urogenital 1 (2) 0 (0) 0.347
Soft tissue 4 (7) 1 (1) 0.050
Central nervous system 0 (0) 2 (2) 0.544
Length of stay, h 205 (85–416) 64 (25–158) <0.001
28 day mortality 17 (28) 12 (10) 0.005
 Data are presented as median (interquartile range) or number 
(percentage) where appropriate.
SIRS = Systemic inflammatory response syndrome; more than one 
location could be recorded as the diagnostic site of (suspected) sepsis.
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16 patients had transient AKI sCr ( table 2 ). Plasma NGAL 
data were missing for 15 patients (AKI sCr 6, noAKI sCr 9) 
and urinary NGAL data were missing 21 patients (AKI sCr 
7, noAKI sCr 14), for which imputed data were used. Ad-
mission serum creatinine was higher in the AKI sCr group 
compared to the noAKI sCr group (p < 0.001). The mean 
urine output and lowest hourly urine output during the 
first 6 h were lower in AKI sCr than in noAKI sCr . Plasma 
and urinary NGAL were higher in AKI sCr compared to 
those in the noAKI sCr group (plasma NGAL: p < 0.001; 
urinary NGAL: p < 0.001).
 Multivariate Models 
 In order to assess how the predictive ability of NGAL 
was related to other risk factors for AKI sCr , we performed 
univariate and multivariate Cox proportional hazards re-
gression analyses. Univariate Cox analyses are reported 
in online supplemental table S1 (for all online suppl. mate-
rial, see www.karger.com/doi/10.1159/000447602). In the 
multivariate model without NGAL – using stepwise back-
ward elimination – pre-admission serum creatinine, sepsis 
and lowest hourly urine output were significant predictors 
for  AKI sCr ( table 3 ). The addition of NGAL to the multi-
variate model – and subsequent stepwise backward elimi-
nation – resulted in pre-admission serum creatinine be-
coming a nonsignificant predictor of AKI sCr , and NGAL, 
sepsis and lowest hourly urine output remained significant 
predictors. The AUROCs for the univariate NGAL and the 
multivariate models are shown in  table 4 . NGAL as a uni-
variate predictor was not inferior to the multivariate mod-
el without NGAL at all time points, whereas the addition 
of NGAL to the multivariate model slightly increased the 
AUROC of predicting AKI sCr at 24 and 72 h after admis-
sion. Specifically, the improvement in AUROC by adding 
NGAL to the multivariate models seems mainly to be due 
to better classification of patients without AKI sCr within 
the first 24 h ( table 5 ). While a similar effect is present in 
the multivariate urinary NGAL model for patients without 
AKI sCr within the first 72 h, the multivariate plasma NGAL 
does not improve the classification of patients with and 
without AKI sCr within the first 72 h.
 Optimal Cutoff and Test Characteristics 
 Because plasma and urinary NGAL as a univariate pre-
dictor for AKI sCr was not inferior to the multivariate mod-
el, we calculated the test characteristics of the optimal cut-
off values for NGAL as predictors of AKI sCr occurrence 
within 24, 48 and 72 h of ICU admission. The result of this 
analysis is shown in  table 6 , and the 2 × 2 tables for the op-
timal cutoff values for NGAL are reported in online sup-
Table 2.  Renal data
Variable AKIsCr NoAKIsCr p value
Number 61 115
Urine output during first 6 h
Time from admission to oliguria, h 2 (1–3) 1 (1–2) 0.080
Cumulative oliguria duration, h 4 (3–5) 3 (2–4) 0.003
Mean urine output, ml/kg/h 0.48 (0.24–0.71) 0.66 (0.47–0.88) 0.001
Lowest hourly urine output, ml/kg 0.25 (0.1–0.35) 0.33 (0.24–0.4) 0.002
Diuretics used during first 6 h 0 (0) 3 (3) 0.552
AKI by serum creatinine criteria
Time from admission to AKIsCr, h 1 (0–14)
Transient AKIsCr 16 (26)
AKIsCr within 24 h 53 (87)
Highest AKIsCr stage reached within 24 h 43 (70)
Highest AKIsCr stage within 72 h
AKIsCr stage 1 31 (51)
AKIsCr stage 2 20 (33)
AKIsCr stage 3 10 (16)
Renal replacement therapy
Need for renal replacement therapy 12 (20) 0 (0) <0.001
NGAL 4 h after admission, ng/ml
Plasma NGAL 349 (192–566) 150 (86–216) <0.001
Urine NGAL 754 (186–4,124) 99 (52–228) <0.001
 Data are presented as median (interquartile range) or number (percentage) where appropriate. Oliguria is defined 
as hourly urine output <0.5 ml/kg.
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plemental tables S2–S4. The optimal cutoff for plasma 
NGAL across the different time points resulted in positive 
likelihood ratios (PLRs) ranging from 4.6 to 8.2, whereas 
the optimal cutoff values for urinary NGAL led to PLRs 
ranging from 2.2 to 2.6. For AKI sCr within 48 and 72 h, 
plasma NGAL was able to correctly predict 80% of patients 
with and without AKI sCr based on the optimal cutoff.
 Discussion 
 The main finding of this post-hoc analysis is that 
NGAL can be used in a clinical setting to discriminate 
between oliguric critically ill patients with AKI sCr within 
the first 72 h from oliguric patients with a functional re-
versible glomerular adaptation. In an oliguric patient 
with known risk factors, the addition of NGAL improves 
the ability to rule out AKI sCr . Furthermore, univariate 
NGAL is not inferior to a multivariate model of known 
risk factors, and NGAL can be used to identify or exclude 
AKI sCr in oliguric patients even when pre-admission se-
rum creatinine value and other risk factors are unknown. 
Given these findings, clinicians can use NGAL to identify 
patients with oliguria due to functional adaptation during 
the early ICU admission. In other words, when oliguria 
occurs, low NGAL values may rule out structural cellular 
damage signifying AKI sCr .
 Our results partly agree with previous literature on ol-
iguria and AKI in the critically ill. A recent study in criti-
cally ill patients with new-onset oliguria strongly suggests 
that not all episodes of oliguria carry the same risk for 
worsening renal function  [21] . In contrast to our analysis, 
only patients with 6 consecutive hours of oliguria at some 
point during the ICU admission were included and wors-
ening renal outcome was defined as both serum creatinine 
and urine output defined AKI. However, as the occur-
rence of oliguria takes place farther from the initial renal 
hit, biomarkers with a time course similar to NGAL may 
become less informative  [11] . In our study, this is illus-
trated by the decrease in NRI and IDI for plasma NGAL 
when predicting AKI sCr within 72 h when compared with 
the prediction of AKI sCr within 24 h after admission.
 This study has several strengths: first, we showed that 
NGAL measurements in a patient group with a high pre-
test probability, such as oliguric patients, are of addition-
al value for the early diagnosis of AKI sCr and can be done 
in a clinically practical manner. Limiting NGAL measure-
ments to a high pre-test probability population improves 
the cost-effectiveness of biomarkers for AKI  [22] . Second, 
considering its time course, NGAL only improves the dif-Ta
b
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ferentiation between functional oliguria and oliguria due 
to renal injury within a relative short time after the initial 
renal injury. Thus, NGAL is best suited for use early dur-
ing the ICU admission or shortly after an event leading to 
the initial renal injury. Lastly, in oliguric patients NGAL 
can be used to identify those without AKI sCr without hav-
ing to wait for a second serum creatinine measurement or 
search for a pre-admission serum creatinine value. Given 
the lag time, the measurement frequency of serum cre-
atinine, and the paucity of available pre-admission data, 
NGAL provides early information on renal outcome.
 This study has several potential limitations: first, be-
cause this study was a post-hoc analysis of a prior prospec-
tive dataset, future studies are needed to validate our find-
ings. Second, the lack of an adequate gold standard to diag-
nose AKI sCr distorts the performance of any biomarker 
 [23] . Therefore, injury biomarkers have the required po-
tential in conjunction with functional markers such as se-
rum creatinine and urine output. Furthermore, in our clin-
ical practice serum creatinine is measured at admission 
and thereafter at least once daily at 6.00 a.m. While serum 
creatinine may take up to 24 h to increase after a reduction 
in glomerular filtration  [24] , measuring serum creatinine 
once daily could delay the recognition of AKI sCr . Moreover, 
since we did not correct the measured serum creatinine 
concentration for the cumulative fluid balance in the first 
72 h of ICU admission  [25] , it is possible that some patients 
were incorrectly classified as not having AKI sCr . Third, to 
calculate the hourly urine output from irregular collection 
intervals, we assumed that urine flow was constant during 
each interval, which ignores any effects of treatment or 
 disease progression during a single period of variable 
length, which could increase or decrease urine output. Ad-
ditionally, collecting enough urine to measure urinary 
NGAL is difficult in patients with a very low urine output, 
which may explain the reason behind some of the missing 
values for urinary NGAL. The missing data rate for plasma 
and urinary NGAL measurements were 8.5 and 12%, re-
spectively, due to interventional procedures or transport at 
the time of collection. We used multiple imputations using 
predictive mean matching of NGAL at admission, 4 and 8 h 
after admission to gather valid data to use as a surrogate. 
Lastly, we did not normalize urinary NGAL concentrations 
for urinary creatinine concentration, since urinary creati-
nine data were not available and doubts remain about the 
necessity for such a correction  [26, 27] .
 The main clinical application of our findings is that it 
provides early awareness, which should trigger interven-
tions to stop further renal injury in oliguric patients with 
NGAL above the cutoff value. Decision algorithms simi-
lar to the one proposed for cardiac-surgery-associated-
AKI could be used to triage patients and resources  [28] . 
In this population with possible AKI sCr , fluid resuscita-
tion should be limited to the restoration of systemic he-
modynamic variables, and nephrotoxic agents should be 
discontinued. In a research setting, NGAL is able to adjust 
the inclusion criteria to create early intervention studies 
similar to the STOP-AKI trial  [29] currently including 
patients only after serum creatinine starts to increase, re-
ducing the lag-time before interventions are started.
 More importantly, measuring NGAL may lead to the 
differentiation between structural renal injury and func-
tional adaptation. Patients with higher NGAL but with-
out an increase in serum creatinine should be classified as 
subclinical AKI sCr  [23] . These patients have worse out-
comes than those with a low NGAL value and no increase 
in serum creatinine most likely due to adequate renal re-
serves  [30] , suggesting that subclinical AKI sCr should be 
considered similar to AKI sCr with elevated NGAL levels. 
Conversely, patients with AKI sCr may have relatively low 
NGAL levels due to glomerular impairment without tu-
bular injury, which is associated with worse outcomes 
than those with low NGAL and no serum creatinine in-
crease  [23, 30] . Whether these patients should be treated 
as AKI sCr or as a third entity in the AKI spectrum remains 
to be determined.
 In summary, NGAL is able to discriminate between 
critically ill patients with oliguria associated with AKI sCr 
and those with oliguria due to functional adaptation. 
More specifically, NGAL as part of a multivariate model 
is able to exclude AKIsCr, whereas NGAL as a single 
marker can identify oliguric patients at risk for AKI sCr . 
Thus, NGAL could be used to aid clinical management in 
patients presenting with early oliguria. Guided by NGAL, 
clinicians can reduce further renal injury and identify pa-
tients with subclinical AKI sCr . However, since serum cre-
atinine is an imperfect diagnostic standard for factual re-
nal cellular injury, further prospective studies are needed 
to confirm our findings.
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